Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2018

View Archived Issues

Tumors, T cells, TFs

DWORF binding dwarfs PLN, helps failing hearts

"Typical" screening method yields novel antifungal drug class

Cytokinetics announces new cardiovascular candidates and updates pipeline progress

Increased risk of migraine in African-American children carrying common variants at 5q33.1

Positive data announced from second phase I study of intranasal betahistine

Podocalyxin as a promising new biomarker in women with polycystic ovary syndrome

Urocortin 3 is involved in the pathophysiology of diabetes

ONO-2910640 shows antidepressant-like effect in animal models of depression

PDT with exendin-IRDye700DX slows tumor growth in GLP-1R-positive tumor models

GeNeuro gives update on pHERV-K antibody program for ALS

Transgene initiates phase I/II trial of TG-6002 in advanced gastrointestinal tumors

Hutchison China MediTech initiates phase I study in China with HMPL-523 for AML

Aslan begins phase I study of ASLAN-004 for atopic dermatitis

Merck & Co. discovers antimycobacterial oxazolidinones

Beijing Jacobio Pharmaceuticals, Jacobio-Alpha Pharmaceuticals patent PTP2C inhibitors

Pseudolysin inhibitors presented by Antabio SAS

Novartis discloses protein atonal homolog 1 activators

New 5-HT2C receptor agonists described by AbbVie

Bristol-Myers Squibb discovers PD-1/PD-L1 interaction inhibitors

Eiger reports phase II data on pegylated interferon lambda in HDV infection

MeiraGTx and Janssen enter gene therapy research collaboration and evaluation agreement

GenSight reports 72-week data from REVERSE phase III trial of GS-010 in LHON

Proteostasis updates status of doublet and triplet cystic fibrosis programs

Phase II study of rozanolixizumab achieves proof of concept in myasthenia gravis

Enanta initiates phase IIa study of EDP-938 in RSV challenge model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...